NIH-CAP 2005-06 Participating Companies
21st Century Medicine, Inc.
Rancho Cucamonga, CA
21st Century Medicine, Inc. has developed novel technologies for cryopreservation and long-term storage of
biological tissue slices. Tissue slices are used pervasively during pharmaceutical drug discovery and
development, however their use is problematic. Because these tissues can not currently be effectively
stored, extensive on-site live animal preparations are required. 21st Century Medicine is currently validating
cryopreserved neural, kidney, liver, and intestinal tissue for ADME/Tox testing applications.
Ready-to-use tissue slices configured for specific testing requirements will significantly increase throughput,
reduce on-site testing costs, reduce variation, and further the potential for analytical standardization.
Preservation systems for clinical applications are also under development.
ABIOMED, Inc. is a leading developer, manufacturer and marketer of medical products designed to assist or
replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000™
Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of
all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the Impella®
Recover™ minimally invasive cardiovascular support systems under CE Mark approval. The Company’s
AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an
Investigational Device Exemption from the United States Food and Drug Administration.
Acme Express, Inc.
Acme Express, Inc. develops healthcare staff scheduling software that cuts schedule-making costs by 80%,
optimizes the schedule, and eliminates paper work. Doctors On Call Schedule (DOCS) Request Module
mitigates the “negotiations” between staff and the off-time administrator. Generator Module optimizes a fair
and accurate schedule. Consolidation Module standardizes and consolidates the entire enterprise call
schedule. DOCS eliminates schedule inequity and frees senior medical staff to focus on healthcare delivery
rather than contentious scheduling issues.
Our mission is to dramatically increase the productivity of healthcare schedulers.
Our vision is to be recognized as the pioneer in web-enabled medical staff scheduling worldwide.
Adherence Technologies has developed AccuNurse™, a voice-activated and hands-free system that is
revolutionizing long-term care staff documentation, education, and communication. AccuNurse integrates
cutting-edge speech recognition, VoIP and Internet technologies with its own proprietary software that
further improves speech recognition accuracy and promotes extreme ease of use. We also develop
interfaces between AccuNurse, clinical software, other wireless systems, and the facility’s main phone
system. We install a turnkey system, train the trainers, and provide outstanding client support for this
transformation technology. AccuNurse benefits include dramatically improving quality of care and risk
management while reducing nursing home costs.
Advanced Brain Monitoring, Inc.
Advanced Brain Monitoring, Inc. develops and delivers innovative solutions for sleep apnea diagnosis,
memory dysfunction measurement and alertness monitoring. Advanced Brain Monitoring helps clinicians
provide better patient care at lower cost with products that combine laboratory level accuracy with the
portability, ease of use and affordability of consumer electronics. The company has chosen to focus on the
highly prevalent, underdiagnosed OSA, but Advanced Brain Monitoring systems are applicable to other
sleep and neurological disorders. Advanced Brain Monitoring systems make possible the widespread use
by physicians, dentists, industrial/transportation companies, and consumers.
Aerophase Inc. has developed a new Metered Dose Inhaler (MDI) that uses a better propellant and aerosol
valve. Most MDIs used to treat asthma still use CFC (chlorofluorocarbon) propellants and all CFC MDIs will
be removed from the market to comply with international environmental laws to stop all CFC production.
The new HFA (hydrofluoroalkane) propellant MDIs cost 3-5 times the CFC propellant MDIs. The Aerophase
MDI is superior to CFC and HFA MDIs with better dose control, higher drug delivery efficiency, less than 1%
of the current propellant cost and less than 0.1 % of the environmental impact.
Agave BioSystems, Inc.
Agave BioSystems has broad capabilities in molecular and microbiology as well as microfabricated and
nanoscale systems. The company’s sophisticated laboratories are complemented with access to a broad
range of research and development tools and facilities at Cornell University. Recently we have made
important developments in flow cytometry that will lead to two product lines: A suite of novel assays are
currently being developed that utilize microspheres and quantum dots. The advantages of these assays are
both improved sensitivity and multiplexing capabilities. Additionally, a simple yet flexible microscope-
mountable flow cytometry instrument has been developed. This instrument provides a low-cost alternative
to conventional flow cytometers and enables new experimentation.
Alan Penn & Associates, Inc.
Alan Penn & Associates, Inc. develops and commercializes cutting-edge diagnostic image tools that enable
clinicians to improve outcomes by detecting cancers earlier and more accurately. Our initial product,
CADimas™, is the first FDA-cleared computer-aided-detection (CAD) system for breast MRI that helps
radiologists screen for and diagnose breast cancer using both lesion shape (morphology) and timing of
contrast uptake (kinetics). R&D has been conducted in collaboration with leading researchers and clinicians
at eight major institutions and funded with $3.0M in SBIR grants from National Cancer Institute.
CADimas™ is currently in beta testing. IP is protected by patents and trade secrets.
AmberGen Inc is a molecular diagnostics company focusing on the development of innovative high-value
diagnostics for complex diseases. Our research is based on the relationship of disease phenotype with
changes in regional and global methylation that occur at the DNA level. We have exploited this
phenomenon and developed assays for the early diagnosis of lung cancer and to improve the categorization
and treatment of asthma. We have identified novel Asthma DNA methylation biomarkers (AsDMBs) and
applied them within a non-invasive, cost effective and easy to use diagnostic format. The patented
prototype diagnostic assay is being validated in a clinical study.
AnaBus synthesizes technological and analytic advances to create efficient and original solutions in the
areas of marketing technology, software development and business analytics. Driven by innovation, we
apply technology to perform complicated analytics with greater clarity, disseminate information more widely,
and solve problems more cost-effectively for our clients.
-created online surveys for market research projects, performing the development, hosting, recruiting, and
statistical analysis in-house.
-developed an online analytics software platform implementing the propensity scores methodology
-developed automated ATM survey respondent compensation system -ran a national sample, large scale
data collection and business analytics project.
APD Life Sciences
State College, PA
ADP Life Sciences, Inc. developed a disposable detector for assessing conditions within a variety of sealed
containers. We offer this patent-protected, non-invasive, low-cost detector under sublicense agreement for
biomanufacturing applications. Based upon fluorescent bioindicators, this detector allows for immediate
assessment of internal pH, oxygen tension and microbial contamination, and is useful for (a) conformance
with developing regulatory requirements for PAT protocols; (b) adjustment of processes for optimum product
production; and (c) early detection of undesired organisms. Given our exceptionally broad experience in
many applications, we can work with the licensee to validate and optimize prototypes and protocols.
ApoLife has developed platform expression technologies for the rapid and cost-effective screening and
production of recombinant proteins and fully functional human antibodies. The market for therapeutic
antibodies is expected to grow to $30 billion by 2010. ApoLife’s yeast system has applications in (I)
acceleration of antibody screening and discovery from either hybridoma subclones or phage display
libraries, (II) cost-effective production of recombinant proteins and antibodies.
ApoLife’s process requires 1/3 the time for production, thus lowering the cost of capital investment, and has
the potential of lowering the cost of final products by up to 50%. The company employs Bakers yeast, S.
cerevisiae, which has been used for manufacturing of several FDA approved therapeutic products thus
providing regulatory competitive advantages over other alternate expression systems. By applying ApoLife’s
proprietary “Twin Cassette” expression system, biopharma and biotechnology companies can accelerate the
process of bringing the new therapies to market and help reduce the healthcare costs.
Artann Laboratories, Inc. (Artann) is an innovative research company developing a wide range of novel
biomedical technologies and products. Patented inventions of Artann include a variety of imaging modalities:
mechanical imaging, new approaches to ultrasonic and magnetic resonance elasticity imaging, and shear
wave elasticity imaging. Artann also introduced several new medical diagnostic devices, including skin
elasticity analyzer, muscle water content tester, colonoscopy force monitor, and a portfolio of scanning bone
ultrasonometers. A new area of Artann research is biomedical and industrial applications of the time
Atom Sciences, Inc.
Oak Ridge, TN
Atom Sciences, Inc. (ASI) was founded in 1980. Its original charter was to commercialize a laser-based
analytical technology called resonance ionization spectroscopy (RIS) that was developed at Oak Ridge
National Laboratory. The company operated for several years as an RIS analytical instrumentation and
service company. From this highly specialized market, the company diversified into the designing and
installing custom Time-of-Flight (TOF) mass spectrometers. Based on its work in TOF analysis of DNA
microarrays, the Company has recently begun developing new technologies related to improving the way
genetic information is acquired.
Azevan Pharmaceuticals, Inc.
Azevan Pharmaceuticals is a drug discovery and development company producing novel therapeutics for
disorders of stress, mood, and behavior. The first series of clinical candidates selectively block the effects of
arginine vasopressin (AVP), a naturally occurring chemical signal in the body involved in the
pathophysiology of conditions that include stress-related affective illness, impulsivity/inappropriate
aggression, and menstrual-related disorders. The chemistry platform can be manipulated to target other G-
protein coupled receptors, including high value targets such as the cannabinoid-1 receptor for addiction and
obesity. The receptors targeted by Azevan are also implicated in certain cancers and cardiovascular
BCR Diagnostics has developed a unique biosensor (termed "80K-biochip") based on using engineered
spores as fluorogenic nanodetectors. The disposable 80K-biochip provides an optimal combination of
speed, specificity, sensitivity, and cost effectiveness that is currently unmatched by any other device.
An advanced application of the 80K-biochip is for detecting contaminating bacteria in platelets intended for
transfusion. Other applications include sterility assurance, detection of weaponized biological particles, and
A prototypic biosensor has the following specifications:
1. Sensitivity to individual biological particles
2. Testing time of about 15 minutes
3. Cost-effective testing based on disposable biochips
4. Cost-effective instrumentation
BioAssessments is developing a promising biological marker into a useful assessment technique. The initial
clinical applications include assessing such diverse medical concerns as attention problems and
hypertension. The value of our product lies in: a) reducing trial-and-error in selecting medications; b) more
efficient titration of medications; and c) identifying individuals who might respond adversely to medications.
Our technology could also be used as an alertness monitor for operators performing mission-critical tasks in
military and industrial operations. BioAssessments currently builds custom monitoring systems and provides
extensive analytical services for researchers at major universities and hospitals to measure this biological
'BioDetection Instruments, LLC was formed in 2002 to commercialize technology for the rapid detection of
food pathogens. Its intellectual property portfolio forms a set of instrumentation characteristics that greatly
improve the speed of detection, lower detection limits, and provide quantitative results. The instrumentation
under development is designed for tabletop use in a processing plant environment with minimal operator
training requirements. The company's mission is to improve the safety and quality of world food supplies
through high-performance biosensors, assay kits, and instruments for the rapid detection of food pathogens
and chemical residues.
Biomedical Acoustics Research Company
The Biomedical Acoustics Research Company develops innovative medical diagnostic modalities based on
multi-sensor computer-assisted auscultation (“intelligent stethoscopes”). Our technologies simply and
instantly provide useful, accurate and low cost information from painless, safe and portable units. We
combine cutting edge digital signal processing, sensor and computer technology with compassionate and
informed medical knowledge to help meet important medical market needs. We’re passionate about the
tremendous opportunities for implementing these techniques to assist in the diagnosis of many
gastrointestinal, pulmonary, musculoskeletal, and cardiovascular conditions.
Biomedical Development Corporation
San Antonio, TX
Frio Technologies is a specialty pharmaceutical company dedicated to treating and preventing infections
transmitted through the oral cavity. This is an important emerging market with no market leader. It is
believed by many that the oral cavity is a route to infection leading to stroke, heart disease, diabetes,
rheumatoid arthritis, and causing infections in cancer patients, organ transplant recipients, and others.
Our first product is an oral rinse to treat gingivitis, which is often the first clinical symptom of disease. We
have successfully completed Phase I safety studies and are seeking investment for Phase 2 efficacy and
Bioscience Development Inc
New York, NY
The Company is dedicated to developing diagnostic assays in immunologic and infectious diseases,
including Lyme disease, that will be useful to guide therapeutic decisions for humans and animals.
Our company develops software for use in research. The software is used by pharmaceutical companies,
universties, and other research organizations.
San Diego, CA
To address the need for new respiratory and cardiac drugs, BioTechPlex/Ceraltics provides cell based HTS
screening services and target validation. Through the simultaneous measurements of multiple fluorophores,
MAPR provides dynamic fingerprints of the interaction of the “drug” with the cellular target site. It is 1000
times faster than competitive systems, yet has a higher sensitivity and specificity. Drug discovery is further
enhanced through screening of “pathogenic” engineered cell lines for asthma and COPD. Target sites are
validated with cell culture-based systems for ciliary activity, water transport, cardiac myocyte beat rate and
QT interval. We predict profitability in the 3rd
Calibrant Biosystems, Inc. discovers, develops, and commercializes protein biomarkers for the diagnosis
and treatment of human disease. Calibrant’s targeted approach to biomarker discovery provides competitive
advantage through proprietary proteomics technologies which are uniquely compatible with limited clinical
tissue samples. The company’s strategy is based on developing a robust biomarker patent portfolio through
targeted collaborations with leading clinical researchers, and biomarker out-licensing to established
pharmaceutical and diagnostics companies.
Callida Genomics, Inc.
Callida Genomics, Inc. develops and sells advanced whole gene and genome resequencing products and
services using proprietary ProbeUniverseTM and combinatorial SBH technologies. Universal Array based
HyChip® and SingleMoleculeGenomeChip have broad applications in research, drug development, and
diagnostics for personalized medicine. Universal Array based HyChip® enables reads of 6kb long
sequences in a simple two-hour bench assay at lower cost. The HyChip® system further enables high re-
sequencing throughput with one inexpensive standard array scanner.
CCC Diagnostics LLC
CCC Diagnostics LLC (CCCD) is developing a medical diagnostics technology to establish drug response
guides for selection of effective chemotherapy. This information aids physicians in determining a
personalized treatment regimen effective for individual cancer patients. The service provided by CCCD is to
characterize drug response indicators of tumors by quantitatively measuring the appropriate biomarkers in
tumor cells/tumor tissues or circulating cancer cells of the patients. The validated technology is ready for
clinical trials. CCCD plans to enter a partnership with hospitals, institutions or companies in clinical trials
followed by commercialization of this patented protected technology and service.
ChanTest has offered drug safety testing and discovery services to biopharma since 1998. The company
has grown from 2 to 35 employees, has annual revenues of about $6MM and has always been profitable.
ChanTest has a reputation for providing expertise, accuracy and urgency to its customers. The company is
especially expert in the area of ion channels. ChanTest services include proprietary high throughput assays
of ion channel function and trafficking and expression of surface membrane proteins in general. Other
services include automated patch clamp, GLP in vitro assays and a growing library of cell lines expressing
important ion channels. A proprietary antiarrhythmic drug was discovered serendipitously. The drug is safe
in man and a Phase 2 proof of concept clinical trial received support in a pre-IND meeting at FDA.
Chemica Technologies, LLC
Chemica Technologies, LLC is a research-oriented, biotech company. Our mission is to develop medical
and pharmaceutical products and therapies that significantly improve and enhance the health and quality of
life for people world-wide. Chemica is engaged in both private and Federal fund-based research built on our
expertise in biochemistry, chemistry, chemical engineering, and microbiology. The technologies developed
through our research efforts are licensed to strategic partners and investors both nationally and
East Hartford, CT
Ciencia, Inc. has developed advanced plasmonics biodetection technology for real-time, label-free, highly
multiplexed bioassays in microliter volumes. This technology comprises an instrument, and disposable
microarray chips. Detection of pathogens and proteins in serum, and assessment of immune cell phenotype
and function in bodily fluids have been demonstrated. Applications include biodefense and immune profiling
for diagnosis and assessment of autoimmune, infectious and neoplastic diseases. Ciencia is a privately
held corporation that develops optical sensors and analytical instruments for biodefense, clinical diagnostics,
research, process analysis, environmental monitoring, food safety and forensic/security applications. The
Company is seeking partners to form R&D joint ventures with an option to license the technology.
Clever Sys. Inc.
Clever Sys. Inc. (CSI) develops and delivers software and systems for automated behavior analysis in life
science. CSI’s patent-protected, technology solutions of next generation use intelligent digital video
techniques to monitor and analyze lab animal behaviors, provide more new critical and reliable data for
scientific research in brain disease, drug discovery, genetic phenotyping, and save huge amount of labor.
Our current and potential customers include pharmaceutical companies, biotech companies, and medical
and biological research institutes. CSI’s current focus is on complex lab animal behaviors, though its
technologies can be applied in patient diagnosis, monitoring and rehabilitation, homeland security, market
survey, athletes performance analysis.
Salt Lake City, UT
CogniTech Corporation develops, markets, and sells customized software solutions for data collection,
content management, decision support, simulation, and training. These technologies are applied to a variety
of domains, including emergency response, homeland security, risk assessment, healthcare information
systems, clinical trials, and scientific research. CogniTech Corporation has internationally recognized
expertise in many domains, including healthcare informatics, occupational and environmental health,
computational chemistry, artificial intelligence, sensor simulation, and e-learning technologies.
Communication Disorders Technology, Inc.
Communication Disorders Technology, Inc.(CDT), founded in 1989, has the goal of becoming the market
leader in the development of computer-based technologies for speech and hearing professionals (speech
pathologists, audiologists, and teachers of the deaf), teachers of foreign languages and of persons with
developmental disabilities. Since its beginning CDT has developed speech production and perception
testing and training systems that combine speech-recognition technology with state-of-the-art computer
graphics. These systems significantly increase clinical effectiveness and efficiency. CDT’s internationally
recognized team of investigators has expertise in speech and hearing sciences, psychology, mathematics,
engineering, linguistics, graphical arts, and computer programming.
Conversion Energy Enterprises
Spring Valley, NY
Conversion Energy Enterprises (CEE) is developing laser assisted tissue welding systems which consist of
miniature lasers, surgical handpieces and light activated bioadhesives for repairing wounds, closing surgical
incisions, fixing implants and grafts. These systems will replace sutures and staples for many surgical
applications especially where the surgery is complex or when minimally invasive techniques are required.
The benefits of tissue welding include the reduction in tissue trauma and infection, increased closure speed,
improved healing response and eliminates detrimental effects of wound leakage. CEE's systems will have
widespread use in herniorrhapy, ophthalmic, orthopedic, urinary and gynecological applications.
Core Tech Solutions, Inc..
East Windsor, NJ
Core Tech Solutions, Inc. is a Research, Development and manufacturing company dedicated to the
science of transdermal (TDS), topical and buccal delivery systems. The company is developing transdermal
patches based on proprietary membrane-controlled technology and drug-in-adhesive technology. Core
Tech has developed patches for pain management and hypertension. The company has applied patents for
its transdermal products. The company is seeking partners for its Fentanyl-TDS and Clonidine-TDS
products. The company’s facilities include R&D laboratory in Mount Laurel, NJ and cGMP manufacturing
facility in East Windsor, NJ. The facility is built in compliance with the FDA and DEA requirements.
Creative Action LLC
Creative Action LLC develops and delivers innovative solutions for the Age 55+ Market. Products targeted to
the institutional market improve the quality of life for older adults in long term care facilities and adult day
care centers, while improving staff effectiveness, efficiency and job satisfaction. Based on proven behavioral
interventions, therapeutic solutions increase engagement and social interaction among people with cognitive
impairments; other solutions enable older adults and staff who do not share a common language to
communicate with each other. Products targeted to community dwelling older adults maintain independence
by improving medication adherence and functioning for successful completion of daily activities.
customKYnetics, Inc. is developing exercise and motor retraining devices for use by individuals with
neuromotor disabilities secondary to spinal cord injury or stroke. Several of customKYnetics’ potential
product offerings utilize neuromuscular electrical stimulation (NMES) for the purposes of exercising
paralyzed muscles and generating exercise movements that load bones and joints of the lower extremities.
customKYnetics is additionally developing derivative devices which utilize biofeedback with or without NMES
to assist clients in regaining voluntary control of paralyzed muscles.
Cyber Access Systems
Bryn Mawr, PA
Cyber Access Systems® (Cyber) has developed a patented, user interface allowing individuals with severe
cerebral palsy (CP) or traumatic brain injury (TBI), including those with quadriplegia, to access a computer.
Cyber will produce two products: (a) a microcomputer-based voice output system, called CyberSpeech®,
targeted to persons whose speech is impaired due to CP or TBI, and (b) add-on software to the
CyberSpeech® system enabling persons with CP or TBI who are unable to access a computer via a
keyboard or mouse to use Windows application programs. To meet the mobility needs of the same
population, Cyber will license its user interface technology to manufacturers of power wheelchairs, enabling
severely disabled users to move independently.
Cytograft Tissue Engineering Todd McAllister
Novato, CA Tel: 415-506-0240
CTE produces tissue engineered blood vessels comprised entirely of the patient’s own cells. The
Company’s Lifeline™ vascular graft is targeted at four revascularization indications: hemodialysis patients,
lower limb amputation candidates, pediatric patients with congenital defects (cardiac) and coronary bypass
candidates. Unlike previous technologies, the Lifeline™ graft does not rely upon synthetic scaffolds or
exogenous biomaterials to provide requisite strength. The vessel is fully endothelialized, and is a living
tissue with an inherent capacity to grow/remodel. The Lifeline™ graft is currently in Phase I/II clinical trials
and is the first completely biological tissue engineered vascular graft to be used in man.
Detroit R&D, Inc.
Detroit R&D develops ELISAs for new drug development and assay kits for toxicity screening of drug
candidates. Cause of 90% of hypertension is not known. Thus NON-specific hypertension drugs such as
beta blocker, calcium channel blocker and ACE inhibitors induces fatigue, dizziness, depression or birth
The Company’s patented Hypertension ELISA kit is based on new finding that increased activity of ONE
enzyme is responsible for hypertension. Clinical data obtained with the Hypertension ELISA revealed that
hypertensive urine specimens were significantly different (98% confidence) from normal specimens. New
generation hypertension drugs can be developed using the Hypertension ELISA.
State College, PA
DIApedia is a State College, Pennsylvania company developing new products for the treatment and
prevention of diabetic foot ulcers. To date, we have received $4.2M of NIH SBIR funding to support
development of three technologies: 1) CAD-CAM footwear for diabetic patients; 2) a 3-D Haptic Lens used
to create a digital image of the plantar surface of the patient’s foot; and 3) a Load Relieving Dressing system
for healing diabetic foot ulcers.
Discovery Genomics, Inc.
Discovery Genomics, Inc. (DGI) utilizes a patented, non-viral gene therapy technology, called the Sleeping
Beauty Transposon System, to safely and effectively transfer a gene into the chromosome of the cell,
allowing for long-term, stable expression of the correct protein. To demonstrate this technology in humans,
DGI will sponsor clinical trials at the University of Minnesota Hospital to treat Fanconi Anemia (FA), a rare
and fatal blood disease. Validation of DGI’s proprietary technology is expected to lead to cures for other
genetically based diseases including Hemophilia A & B, and long-lasting treatments for glioblastoma and
Eagle Vision Pharmaceutical Corp
Eagle Vision Pharmaceutical Corp. is a private development stage company with programs building upon
special expertise in the field of injectable imaging agents. Covered by issued and pending patents, the
Company’s product candidates enhance Magnetic Resonance Imaging's (MRI) powerful potential to
revolutionize the diagnosis and management of heart disease, liver disease and cancer, replacing the more
limited, costly and invasive procedures currently used. SeeMore™ (EVP 1001-1) represents a significant
commercial opportunity as the only intracellular heart agent that is not radioactive. Phase II studies in heart
patients are ongoing to demonstrate the superior diagnostic features of SeeMore™ enhanced MRI.
Mercer Island, WA
Engineering Arts is a technology development and manufacturing company currently specializing in
piezoelectric `ink-jet' fluid dispensing technology. Current products include the ActivePipette piezoelectric
microfluidic dispensers, the DE02 SignalGenerator to drive the dispensers and a robotic laboratory
automation instrument capable of transferring (pipetting) sub-nanoliter fluid samples with micron positioning
accuracy. Engineering Arts’ dispensers are used commercially to generate gene expression microarrays. In
collaboration with the Fred Hutchinson Cancer Research Center, Engineering Arts is developing a cell-
based RNAi microarray assay. Engineering Arts is seeking collaborators to develop other applications that
could benefit from microfluidic dispensing and laboratory automation technology.
FEO Medical, Inc.
FEO Medical, Inc., located in West Tennessee, offers our clients a broad range of R&D services including:
mechanical, electronic, optical, software, and systems design; prototype construction and manufacturing
interface; and intellectual property assistance via our in-house Patent Agent. We specialize in LabView and
are National Instruments’ Alliance Members. We have worked with a broad range of clients and
technologies. Government-sponsored projects include multiaperture vision tracking systems and multi-
spectral imaging systems. Products for commercialization include: deep-UV laser delivery and imaging
systems; sleep apnea analysis software; visible lightguide illumination systems; and vacuum-based leak
detection systems. University-based projects include carbon-dating analysis systems.
Founded in 1991, Fermalogic is a research-driven biotechnology company that develops and implements
strain improvement technology for fermentation-based products to lower the cost of drugs and improve the
profitability of pharmaceutical manufacturing. The company's research focus is in industrial microbiology as
it applies to strain and process improvement for the production of antibiotics and other natural products.
Fermalogic's goal is to bring new technology to the pharmaceutical industry to solve real-world problems in
drug production. In response to the never-ending challenge to increase fermentation yield, Fermalogic has
developed a strain improvement process based on its patent-pending FermaChannelingSM metabolic
FM Technologies, Inc.
FM Technologies (FMT) develops technology and instrumentation in the area of high-energy, plasma
physics and materials processing for industrial, medical, defense, and environmental applications. The
company’s expertise covers particle accelerators, electron guns, ion beam sources, cathodes, particle beam
optics, precision measurements and control and power electronics, vacuum systems, microwave heat and
radiation treatment of polymers, metals, ceramics, and composite materials.
Products for commercialization include: High-brightness penning source of continuous ion beams of O-, H-,
Ar+ for biological applications, Microwave joining of ceramics to similar and dissimilar materials, and
Electron beam process for prevention of vacuum breakdown in high voltage vacuum devices.
Frontier Scientific, Inc.
Frontier Scientific, Inc. (FSI) has developed a drug for iron overload treatment. Hereditary hemochromatosis
(HH), also known as iron overload disease or "genetic iron poisoning", is the most common genetic disease
in the U.S.A. according to the U.S. Centers for Disease Control and Prevention (CDC). 1 in 8 are "silent
carriers" of the single HH gene mutation and 1 in 100-200 have the double mutation, putting them at high
risk for developing full blown HH. HH can affect men, women and children at any age. Currently, individuals
with iron overload diseases have phlebotomy treatments, or the removal of a full unit of blood from the
patient, conducted in a medical setting one to two times a week. Now, with the drug under development by
FSI, an oral dosage prior to a meal will inhibit iron uptake, allowing people to lead a normal life style and
save thousands of dollars in medical expenses each year.
St Joseph, MI
GeneGo develops tools for the integration and systems level analysis of high-throughput experimental data
in human biology and medicinal chemistry. Our flagship product, MetaCore™, assists scientists in drug
target selection, validation, and identification of molecular biomarkers. MetaCore™ is an integrated
analytical suite with data parsers, visualization tools and flexible network building algorithms. MetaCore
works with the proprietary content of MetaBase™ our manually curated database of human biology which
allows one to network over 90% of the known human proteins via direct interactions. Our second product,
MetaDrug™, deals with prediction of human metabolism and toxicity of novel small molecules and
General BioTechnology, LLC
General BioTechnology (GBT) is a cell processing company based on novel technologies including methods
and devices specifically related to giving biological cells and tissues shelf life. The company has made
advancements to improve cryopreservation and banking methods for such diverse cell and tissue types as
human pancreatic islets of Langerhans, blood platelets, umbilical cord blood, peripheral blood stem cells and
spermatozoa. Presently, GBT also runs a commercial cord blood bank and anonymous donor and
autologous sperm bank. GBT is registered with the FDA as an HCT/Ps facility and is licensed by the State
of Indiana as a Clinical Blood Center Program.
Genex Technologies, Inc.
Founded in 1995, Genex Technologies is a world leader in 3D Imaging, 3D facial recognition, and intelligent
Genex’s highly accomplished staff of engineers and project managers deliver practical solutions to some of
today’s most challenging imaging needs. With internal expertise in fields ranging from optics to mechanical
design to electronics, Genex’s innovative team solves complex problems every day.
Genex offers solutions and design competencies in the following areas:
High-Speed 3D Capture
3D Editing and Post-Processing
3D Data Manipulation
3D Display The Intelligent
High-Speed Image Processing
Remote, Unmanned Applications
GLSynthesis is a 9-year old, private company that performs laboratory scale (custom) organic synthesis,
drug discovery research, and chemical product manufacturing. Customers include major US and
international pharmaceutical companies, startup drug discovery and "virtual" companies, biotechnology
companies, suppliers of fine chemicals, nutriceutical companies, and academic and research institutions.
Drug discovery, including in vitro and in vivo pharmacology and pharmacokinetics, is accomplished through
corporate contracts and small business (NIH) grants. We have developed the Fluorosome Technique for
drug absorption and disposition studies, and are actively marketing it. We develop, market, and sell several
specialty chemicals worldwide, produced directly by our affiliate company Shanghai GLSynthesis, Shanghai,
Goldfinch Diagnostics Inc.
Iowa City, IA
Goldfinch Diagnostics Inc. was founded in 1997 with the goal of developing diagnostic assays for infectious
diseases. To date its activities have been focused on the development of hybrid recombinant antigens
useful for the diagnosis of Chagas disease. The primary support for these activities has been a SBIR grant
from the NIH.
Gwathmey, Inc. the “The Thinking Pre-Clinical Contract Research Organization” TM
provides both GLP and
non-GLP studies for in vivo and in vitro drug screening for lead compounds, pharmacokinetic, toxicology,
biodistribution studies and efficacy testing in animal models. We work in the Arthritis, Cancer,
Cardiovascular, CNS, Infectious Disease, Diabetes and Obesity therapeutic areas. Our world-class
scientists and state-of-the-art research facilities are used to conduct proof-of-concept and key experiments
for FDA drug approval. We significantly change the risk-reward profile and effectively bridge the difficult gap
between chemistry and biology. Our goal is to conduct efficient, physiologically sound studies in order to
provide high quality data for quality drug development decision making.
Colorado Springs, CO
Ivan N. Rich
HemoGenix specializes in developing and producing sensitive in vitro luminescence proliferation assays to
meet the need in 3 market areas. These include detecting and predicting hemotoxicity during drug discovery
and development, multifunctional research assays for basic research and quality control in stem cell
transplantation and cord blood storage processing laboratories. The HALOTM Platform, fulfils all 3 arenas
as both a contract service and a product line of over 400 assay kit variations. HemoGenix provides these
services and kits worldwide. HALOTM and its applications is one of 4 luminescence assay products within
the HemoGenix intellectual property portfolio.
IA, Inc. / ThreeFold Sensors
Ann Arbor, MI
ThreeFold Sensors, Inc. (TFS) develops and markets portable biosensor instruments and a variety of sensor
cartridges having applications in medical diagnostics and environmental testing. Our sensors provide, in 3
minutes, results of comparable sensitivity to those obtained by immunoassays requiring 4-24 hours. The
technology has been developed through $7.5 million in SBIR grants and is protected by seven pending
patents. Our instrument's small size brings reference lab quality tests to field testing and point of care
settings. Our panel of rapid reproductive hormone tests will be introduced to fertility clinics in 2006.
Sensors for assessing which pharmaceuticals will best treat an individual's cancer are in development.
IBET Inc.’s corporate focus is on research and development of instrumentation for the biochemical,
biophysical, and biomedical sciences. The company’s expertise and experience in biothermodynamics has
inspired development of proprietary technology for monitoring thermal and thermodynamic properties of
macromolecules; specifically, temperature-dependent UV/Vis spectroscopy and ultrasonic velocimetry.
IBET Inc. has developed analytical instruments designed to provide new and unique information about the
thermodynamic properties of biologically important macromolecules and biomolecular interactions. These
instruments address a deficiency in high-throughput thermodynamic methods resulting from the explosive
growth in knowledge of DNA and protein sequence information.
Ichor Medical Systems, Inc.
San Diego, CA
Ichor Medical Systems has developed a powerful, patented electroporation technology for delivery of DNA
drugs. Although electroporation is a broadly utilized method for DNA drug delivery in various animal models,
commercialization of this technology has been hindered by the lack of a reliable and clinically acceptable
means for human administration. Ichor’s proprietary TriGrid™ Delivery System integrates several patented
electroporation technologies into a simple handheld clinical device that enables safe, efficient and
reproducible DNA administration with minimal clinical training. This powerful technology delivers on the
promise of DNA drugs and vaccines, addressing the significant unmet medical needs of numerous
debilitating and life threatening diseases.
INCELL Corporaton, LLC
San Antonio, TX
Mary Pat Moyer
INCELL has developed innovative and patented platform technologies for non-needle vaccine delivery and
intends to make an impact on global health by changing the vaccine delivery paradigm. Its oral and nasal
smallpox vaccines will complete Phase I/II clinical trials by Q3 2006 and provide supportive technology
information to influenza, HIV and other vaccines in development. INCELL manufactures and sells products
to biotechnology and pharmaceutical markets, and provides contract research services relevant to pre-
clinical and clinical products for infectious disease, regenerative medicine, stem cells, chem-bio defense,
and cancer. INCELL has a strong multi-product pipeline, including a cancer nutraceutical in clinical trials.
INFOTECH Soft, Inc
INFOTECH Soft, Inc. specializes in the application of XML and Web technologies to create next-generation
software solutions for health and life sciences research. INFOTECHSoft’s ASPECT clinical trial
management system combines intelligent electronic form and trial models designed around XML Schema,
which contain instructions for sophisticated data verification, automated calculation, and conditional
processing. The system can be deployed in single location studies or large, multi-center clinical trials
communicating over Internet connections. It increases data accuracy and enables timely protocol
compliance monitoring, reducing the overall costs of executing a clinical trial and the total time-to-market of
promising drugs or therapies.
Inframat® is a global leader in the development and commercial sale of powder and solution feedstocks for
thermal sprayed industrial nanocoatings and currently holds over one dozen nanocoatings patents (U.S. and
foreign). Inframat's ceramic nanocoating product, NanoxTM 2613 Thermal Spray Feedstock, which
received an R&D100 Award in 2001, has been in use on shipboard (propeller shafts) for several years and is
currently is "spec’d" and blueprinted with the U.S. Navy. Inframat® has applied similar nanocoatings to
medical applications, and has licensed this patented technology to a major orthopedics company. Inframat®
Advanced Materials, a commercial subsidiary, sells nanomaterials throughout the world.
Integrative BioInformatics, Inc.
Los Altos, CA
Integrative Bioinformatics is a scientific software and consulting services company with expertise in the
modeling and analysis of biological systems. Our software product, ProcessDB, helps molecular cell
biologists, physiologists and pharmacologists manage and test their increasingly complex mechanistic
hypotheses. ProcessDB does this with a powerful but biologically intuitive graphical user interface that helps
biomedical researchers formulate, visualize and test their theories of cellular and physiological function.
ProcessDB allows investigators to know what their theories predict for any collection of experimental
designs, and it speeds discovery of mechanisms that account for all of the available experimental data. By
leveraging database, kinetic modeling, and visualization technologies, ProcessDB supports knowledge
management for research organizations working on complex biological problems.
Intrinsic Bioprobes, Inc.
IBI’s mission is to improve the diagnosis and treatment of disease through the application of novel
proteomics technologies and findings”.
IBI’s proprietary technologies are used in the study of diseases for biomarkers discovery/validation and
subsequent diagnostic application. Presently, IBI operates in the proteomics instrumentation, services and
intellectual property markets, with respective offerings of MASSAY® analytical systems, contract research
programs and licensing arrangements.
Ionwerks, Inc. designs and manufactures a complete line of instrumentation and electronics for Time-of-
Flight (TOF) mass spectrometry. Our patented instrument couples ion-mobility (IM) of MALDI desorbed ions
with orthogonal time of flight (oTOF) mass spectrometry to provide analysis of small molecules unidentifiable
by MALDI alone, such as drugs of abuse, lipids, and neuropeptides. Ionwerks’ revolutionary technology can
simultaneously separate and identify low mass ions while analyzing larger mass ions from intact molecules
and biomolecules. In addition to important biological and clinical applications, the generalized techniques
and instrumentation are applicable to numerous other fields, including materials analysis and environmental
Kinetic Muscles, Inc.
Kinetic Muscles, Inc. products help people with neurological disease such as stroke to improve the use of
their hands, arms and legs. We make the first and only multi-modal active-motion device for home and clinic
based therapy of neuromuscular disability. Says one user, "Regaining my grip has changed my outlook on
getting my life back." KMI is poised to accelerate from the current convergence of neuroscience advances,
a home healthcare trend and its early foothold in the neurotherapy market. Its products are an important,
cost-effective solution that improves the quality of life for millions of people. The accomplishments and
experience of its team have demonstrated a path toward success.
Union City, CA
Kumetrix has developed a unique medical diagnostics technology based on bioMEMS (Micro-Electro-
Mechanical Systems). A single-use disposable silicon microchip, with integrated hollow microneedle
comparable in size to a human hair, punctures the skin, draws a sub-microliter blood sample into the body of
the chip, and performs a specific assay without subsequent blood transfer. The chip mates with the actuator
of a handheld meter, which automatically performs the puncture under microprocessor control, reads the
assay, displays the result, and stores it in memory. This single-step method renders blood testing painless,
rapid, clean, and inexpensive, while requiring no skill from the operator.
Leo Lens Technology
San Diego, CA
Leo Lens Technology, Inc. has developed the next generation product for the lucrative $4 Billion contact
lens industry. With the Leo Lens technology, exact coloring and iris imaging can now be achieved creating a
superior product for the cosmetic and prosthetic segment. This globally patented and FDA approved
technology is ready for manufacturing scale-up. Leo Lens is looking for both strategic and financial partners
to fully commercialize this innovative product.
Santa Barbara, CA
MedSignals™ is a product line of communicating medication devices to aid adherence. The smart pillboxes
alert at pill times, time-stamp usage with each lid opening, upload data to servers daily, and post usage
times on charts for authorized caregivers. As a data collection tool, MedSignals imports easily to
spreadsheets. A handheld MedSignals pillbox showed significantly improved compliance in one NIAID-
funded study. Other models in development include a wireless model for chronically ill children with a GPS
locator. MedSignals will introduce its first commercial model in August, 2006. It will sell through insurance
plans, trade shows, medical supply companies and pharmacies.
Lohocla Research Corporation
Lohocla is a preclinical-stage company focused on the therapy and diagnosis of pain, psychiatric and
addictive disorders. The lead product, DCUK, is a patent protected, novel compound that has demonstrated
biological activity in animals for pain, anxiety, and alcohol dependence. The lead indication is severe
chronic pain. The pain management market is over $32 billion in the USA, and current medications are
suboptimal. To date DCUK has been shown to be safe, and to have significant activity for severe pain.
Lohocla is currently conducting preclinical FDA studies to pursue potential indications for phantom limb pain,
cancer pain, and dental pain.
Business Description: Lucid, Inc. is a medical device and information company that has developed,
patented, and produced confocal microscopes (trademarked as VivaScopes®) that produce images of living
cells for real-time medical imaging and diagnosis in a doctor’s office. VivaScopes®, when coupled with
Lucid’s patented digital pathology PACS system, allows real-time diagnosis of many malignant diseases -
without the need for invasive biopsy. Lucid intends to launch its products for dermatologic surgery followed
by screening of skin cancers. Ultimately the technology can be applied in many other areas of diagnostic
and surgical pathology. Lucid’s business model derives revenues from device sales and from transaction
fees for its digital pathology PACS services. As the installed base of VivaScopes® grows, Lucid will derive
the majority of its revenues from transaction fees.
College Station, TX
Lynntech is an "innovation engine", applying in-depth experience in research, technology development,
prototyping, and product commercialization. We perform research and development for a variety of clients
(leading corporations, Federal R&D and venture capital) helping them meet their strategic goals under the
ever-increasing pressures of faster technology cycles and heightened competition. Our advanced life
sciences chemistries and devices business strategy focuses on creation of value for early and prototype
stage inventions and intellectual property derived internally and/or in partnership with leading university
faculty inventors. Lynntech growth is achieved through partnerships offering cutting-edge technologies for
licensing, and through the creation of investment opportunities in new ventures.
Maine Molecular Quality Controls, Inc.
Maine Molecular Quality Controls, Inc. (MMQCI) provides the biomedical industry with innovative, high-
quality control products for molecular diagnostics. MMQCI products fulfill Federal regulations by monitoring
the entire molecular laboratory test, including extraction. Products are composed of synthetic nucleic acid
constructs stabilized by a unique proprietary matrix. All are uniquely designed to be analyzed as natural
biological samples. Unlike biologicals, MMQCI controls contain multiple mutations in single samples. This
key feature renders the controls comprehensive and cost efficient, allowing more complete quality
assurance. Products are non-infectious, facilitate documentation requirements and provide consistent
results to aid the identification of potential system problems.
Maxwell Sensors Inc
Santa Fe Springs, CA
Maxwell Sensors Inc has developed a proprietary microfluidic bio-disc technology. The microfluidic
chemiluminescence (MCL)-bio-disc products offer multiplexed assays, rapid test results, and significantly
more sensitivity (100 - 1,000 times) and accuracy than the current Point of Care Testing systems. The
technology provides “low cost”, "miniaturization", "integration", and "total automation" for a wide variety of
immunoassay and molecular diagnostic applications. Cardiac markers and infectious diseases panel tests
are our initial market applications.
Microwave Imaging System Technologies
MIST Inc. is an early stage medical device company which has demonstrated an improved system for breast
cancer screening and diagnosis. The addressable market is 40 million women in the US ($4B/yr in screening
service from >$1B of capital equipment). The worldwide market is four times larger.
In human clinical testing of >150 patients at the Dartmouth-Hitchcock Medical Center we have demonstrated
performance equivalent to an MRI at one tenth the cost. This success reflects over $6M invested by the
National Institute of Health in developing our technology.
Intellectual property is issued and wholly owned.
Molecular LogiX, Inc
The Woodlands, TX
'Molecular LogiX is a drug discovery company. The Company is developing a new class of protein-based
therapeutics to treat cancer. Our initial focus is on developing Anti-Cancer Ligands (ACL) directed against
Receptor Tyrosine Kinases (RTK) implicated in cancer. We have developed a potent new “Pan-HER” ACL
that has the potential to be a valuable new weapon in the fight against cancer. This “First in Class”
compound reflects an entirely new approach to interfering with the RTK-dependent progression of disease.
The Company’s business strategy is to develop the drug leads it creates through Phase II clinical trials and
then partner them with larger biotechnology and pharmaceutical companies.
New Haven, CT
Molecular NeuroImaging, LLC (MNI) is a neuroimaging services company specializing in the efficient
application of scintigraphic biomarkers in drug development and clinical research for neurodegenerative and
neuropsychiatric disorders. MNI provides services across the pre-clinical and clinical spectrum including
radioligand development, design and implementation of Phase 1 to Phase 4 clinical imaging trials, and
customized clinical imaging site coordination and management in multi-site imaging studies. Our strong
emphasis is on using investigational radiotracers with quantitative imaging outcome measures as diagnostic
tools and/or for assessing disease mechanism or progression. Our focus is on developing radioligands as
tools for human research.
MRPath, Inc. specializes in the conduct of high performance magnetic resonance imaging (MRI) protocols
for accelerating the discovery of new biopharmaceutical targets and evaluation of their safety, and rodent
models of disease and toxicity. Our technology enables the study of effects in the same animal over
extended times, and three-dimensional imagery of in-context bio-structure with exceptional resolution and
field of view. Unlike previous technologies, the company’s technology enables quantitative morphological
measurement. MRPath integrates its MRI with complementary imaging technologies into image-centric
study report formats, which are available to customers in a web-enabled document and image management
Nanoprobes, Incorporated researches and develops novel technology for the detection and visualization of
biological targets using targeted metal nanoparticles and metallographic reactions. The company is
developing improved X-ray contrast agents for angiography and vascular imaging which provide enhanced
sensitivity, combined with low toxicity and very low viscosity, thus minimizing vascular damage and enabling
imaging in organs such as the brain, or in obese patients where current contrast agents are not well
tolerated. These reagents are also applicable to the specific imaging of cancer, and high-resolution imaging
of smaller blood vessels and features (Micro-CT).
Neuronautics, Inc. (“NNI” or the “Company”) was founded in 1997 with the mission to develop diagnostic and
therapeutic treatments for the early detection and eventual prevention of Alzheimer’s disease (AD) and other
related neurodegenerative disorders. These disorders are characterized by the formation of structures called
neurofibrillary tangles (NFTs) from molecules of tau protein that associate into insoluble polymers. The
Company believes that drugs that can inhibit or prevent NFT formation will prevent the progression of AD or,
given early diagnosis, potentially reverse the course of the disease. In collaboration with leading experts and
renowned academic institutions, NNI has discovered several potent anti-tangle drug candidates. Eventually,
NNI anticipates partnering with major pharmaceutical companies to take these compounds through the
clinical testing necessary to support FDA approval.
NOCwatch International, Inc.
Crystal Bay, NV
Our nation’s elderly fall about 10 million times per year, frequently incurring major disability and significant
social and economic costs. NOCwatch has completed two clinical trials resulting in the first device ever
shown to reduce falls and injuries in this high-risk population. It does so with a small, inobtrusive patch
attached like a band-aid to the patient's thigh that reliably alerts staff or family that a patient is trying to get
up unassisted, without sending false alarms. The alarm in the room reminds the patient that they are not to
get up unassisted (which works particularly well with dementia patients), and can also be connected to a
nurse call system to call a nurse or page a relative. The low-cost, Class I-exempt device is worn for up to
three weeks before being disposed of with regular waste, and can be worn while bathing and during x-rays,
MRIs, etc. More information can be found at www.nocwatch.com.
San Diego, CA
NovaRx has developed and utilized a technology that has significantly prolonged survival and improved the
quality of life in cancer patients.
NovaRx is a clinical-stage biopharmaceutical company. It's lead product, Lucanix™, is at the end of a
Phase II clinical trial for the treatment of non-small cell lung cancer. Results demonstrate median survivals
more than twice that of approved drugs with only minor toxicities. NovaRx is meeting with the FDA in the
fourth quarter of 2005 in order to initiate a Phase III clinical trial for Lucanix™ in early 2006.
NovaRx hopes its additional technologies under development will transform cancer into a controllable
disease such as diabetes.
Optimer Pharmaceuticals, Inc
San Diego, CA
Optimer Pharmaceuticals, Inc., a privately held San Diego-based company, has two late-stage drugs to treat
life-threatening bacterial infections under development
and a range of preclinical antibiotics discovered through our powerful carbohydrate drug discovery engine.
Optimer's core competence includes the development of innovative drugs for treating diseases that currently
have no satisfactory therapy. These include antibiotics for drug-resistant bacterial infections, a cancer
vaccine, and "disease-modifying" drugs for osteoarthritis. In the near term Optimer plans to bring in
significant revenues through sponsored research, joint ventures, government grants, and license royalties.
Redwood City, CA
Panomics, Inc., incorporated in California in September 2000, is a biotechnology-based company dedicating
to the development of innovative tools for the functional studies of proteins. Panomics began its official
operations on November 2000 and launched its products on July 2001. Since then, the company has been
launching more than one thousand products to the market. Panomics has established an international
distribution network covering all major countries and is establishing its sales network in North America.
Panomics was ranked #4 among 100 fastest-growing companies in San Francisco Bay area by San
Francisco Business Times and #6 among 50 fastest-growing private companies in Silicon Valley by San
Jose Business Journal in 2004. Panomics has been awarded 7 SBIR/STTR grants of total $2.5M by the
National Institutes of Health (NIH). Panomics has become a profit organization since 2003, Panomics
acquired in 2003 FreshGene, a small biotech company engaged in the development of SNP detection
technologies. Panomics has filed more than 15 patents, 7 of which are issued. Panomics has now 12 full-
time employees; 4 of them are PhD/MD scientists, and it occupies a facility with 6,500 square feet of lab and
office space in Redwood City, California. Panomics also has a strong scientific consultant team including
Michael Rosenfeld, who is the members of National Academy of Sciences.
Paradigm Pharmaceuticals, LLC
St. Paul, MN
Paradigm Pharmaceuticals, LLC is a start-up, for-profit Minnesota limited liability pharmaceuticals company.
The goal of Paradigm Pharmaceuticals is to develop new and active pharmaceuticals for the prevention and
treatment of viral infections and malignancies. Paradigm Pharmaceuticals is currently developing bench-to-
bedside patent-applied technologies towards final product and approval stages in order to produce the
highest quality pharmaceutical and consumer health care products in the world. Complete in house
laboratory set-up with state-of-the-art equipment is established. Extensive research studies have been
conducted and the most beneficial and extraordinary drug candidates have been tested in animal models to
confirm efficacy, potency, and toxicity.
Perinatronics Medical Systems
Perinatronics develops and clinically tests innovative diagnostic medical instrumentation. In obstetrics, we
developed a unique, patented non-invasive fetal heart rate monitor used for advanced antepartum testing
and monitoring during labor and delivery. It is the only device available to non-invasively monitor clinically
significant fetal heart rate beat-to-beat variability. Recently, our priority has been the development of our
innovative patent-pending ECG triggering system to improve cardiac magnetic resonance imaging. This
ECG gating system provides for reliable and robust triggering of the moving heart and coronary arteries. We
work closely with leading physicians at the University of Maryland School of Medicine, Johns Hopkins
Hospital, Barnes Hospital, and the National Institutes of Health Clinical Center.
Persyst Development Corporation
Del Mar, CA
Persyst is the world’s largest developer of software for EEG (electroencephalograph) review and analysis.
Current markets include clinical review, epilepsy monitoring and diagnosis, and ICU monitoring. Our recently
developed AutoLearn™ technology allows patient dependent algorithms to be developed on the fly from
EEG and critical care parameters. The EEG technician marks a single example of the pattern of interest and
the neural networks are trained instantaneously (< 1 s) without user intervention. New examples can be
identified to refine the algorithm without retraining. The same technology allows patient independent
algorithms to learn over time.
PhysioGenix was formed by leading researchers at the Medical College of Wisconsin (MCW) to
commercialize the Founders’ vision of reducing drug failures in clinical trials by improving pre-clinical animal
models for predictive toxicology, drug screening, and target validation. To fulfill this vision the Company has
brought physiology to the genome by engineering multigenic rat models using genetics, genomics, and
bioinformatics to match human disease. PhysioGenix uses these animals to provide contract research
services related to predictive toxicology and therapeutic proof-of-concept to pharmaceutical companies to
help them accelerate their product development processes.
Pinnacle Technology Inc.
Pinnacle develops and commercializes innovative medical devices for animal research. The company
targets the pharmaceutical industry, research laboratories and universities that use over 20 million mice and
rats each year in the United States. Turnkey Pinnacle systems include biosensors, wireless or tethered data
acquisition systems, and software. Pinnacle’s sensors and systems are well suited for high throughput drug
screening, and they enable research that will elevate our understanding of the chemical origins of behavior
and many disorders including: sleep disorders, heart disease, Parkinsons, and Alzheimers.
Platypus Technologies is a Bio/Nanotechnology company. We are developing a new generation of
diagnostics, monitors and sensors based on the use of nanostructured surfaces and liquid crystals.
Platypus technology enables label free detection of proteins, cells, viruses and volatiles. Our products will
allow scientists to monitor large scale outbreaks of diseases such as avian influenza using sensitive, rapid
assays that permit digital acquisition, analysis and sharing of data and that can be conducted in low
technology environments. Platypus technology will also permit the quantitative, individual monitoring of
exposure to environmental toxins, such as pesticides. Our products will be useful in basic research, clinical
medicine, environmental studies and military applications. Platypus has received over $10 million in
competitive SBIR funds to advance the development of this powerful platform technology.
PortaScience Inc. focuses on new product development for point-of-care diagnostic tests which address
clinical and consumer markets. The team has experience in commercializing over 50 FDA approved
diagnostic products, and has licensed out or commercialized five products in the last five years.
Praevium Research, Inc.
Santa Barbara, CA
Praevium Research, Inc. is a developer of compact semiconductor-based sources of broadband optical
radiation for biomedical imaging and other sensor applications. Current development efforts include
broadband sources for Optical Coherence Tomography, multi-wavelength laser arrays for diffuse optical
spectroscopy, and dense laser clusters for near infrared agricultural spectroscopy. Praevium core
technologies include semiconductor wafer bonding, processing, and epitaxial growth, and micropackaging of
semiconductor sources. These technologies are being employed to create sources with maximum
wavelength coverage in conjunction with minimum size and power dissipation.
Premitec, Inc. was founded as a spin-off from the Biomedical Microsensor Laboratory and the Center for
Advanced Manufacturing Processes and Materials at North Carolina State University in Raleigh. The
company uses its expertise in microfabrication technology to provide research, product development and
manufacturing expertise to medical device, diagnostics, genomics and drug screening companies. In
addition the company is developing proprietary biomedical sensors and implant devices.
Premitec’s platform technology combines its microfabriation technology for flex substrates with the
proprietary A-coatTM encapsulation technology enabling the development of flexible, biocompatible
implantable microelectrode arrays and devices used for neurostimulation, in-vivo diagnostics as well as the
development of low-cost, disposable microfluidics components and sensors for in-vitro diagnostics.
Products under development in collaboration with corporate and academic partners and partially funded by
SBIR grants form the NIH are microelectrode array devices for neural stimulation, in-vivo glucose sensors
and novel electrochemical immunosensors.
Therapeutics Research and Development:
Proteomtech, Inc. is a product-driven pharmaceutical research and development company. PTI is based
upon IP for protein refolding (US patent 6,583,268), Pt-Fold TM.
Our focus and core technology is built around developing therapeutic proteins optimally refolded from E. coli
inclusion bodies that are difficult to recover via competing technologies.
Using Pt-Fold, ProteomTech has developed a pipeline of protein drug candidates. Proteomtech holds
worldwide composition of matter, method of manufacturing and methods of treating cancer patents for a
protein therapeutic candidate for oncology, and has submitted method of manufacturing patents for protein
therapeutic candidates for chronic obstructive pulmonary disease and thrombolytic indications.
East Providence, RI
ProThera Biologics develops "theranostic" and therapeutic products for serious human diseases such as
sepsis and cancer. Theranostics represent a new market area with enormous potential for growth which
utilize predictive tests to make critical, personalized treatment decisions. The company is currently focusing
on novel uses of natural plasma protease inhibitors (Inter-alpha inhibitors) which are involved in the
pathological processes of systemic inflammation and cancer metastasis. Utilizing inter-alpha inhibitors as
integrated theranostic and therapeutic biomolecules, ProThera Biologics will target sepsis and cancer, a
clinical arena representing wide-spread patient populations with a significant unmet medical need.
San Jose, CA
QED Labs provides software for solving complex computational biology problems. We develop
computational research tools for three-dimensional structural determination from electron microscopy data
that enable biologists, at all levels of structure determination, to easily process their data. QED Labs
accomplishes this with innovative software that guides user on how, when, and why to perform data
Sci-Tec, Inc. is a microarray technology company offering equipment, software, consumables and reagents
for life science research and biomedical applications.
Sci-Tec's core product is AuroGen microarray system, which has a unique capability to detect and quantify
DNA, RNA and proteins on high-density microarrays without chemical modification of target molecules. The
unique, yet affordable microarray platform can be used in various applications offering advantage of
personal microarray system to researchers and medical practitioners working in the fast expending fields of
genetic analysis, medical diagnosis, environmental analysis, drug discovery, forensic analysis, and
SibTech, Inc. is developing VEGF-based imaging constructs for targeting and imaging angiogenesis. The
constructs for fluorescent and nuclear medicine imaging, based on proprietary single-chain VEGF, are
successful in animal models and strategies for clinical development are being explored. In developing these
constructs, SibTech utilized its proprietary technology for conversion of biopharmaceutical proteins into the
carriers of therapeutic and diagnostic agents. SibTech is offering this technology for licensing and/or co-
development to the companies that wish to expand applications and patent life of their proprietary
SoloHill Engineering, Inc.
Ann Arbor, MI
SoloHill develops and delivers microcarrier technology for use in the human and animal pharmaceutical
industries. SoloHill has responded to industry needs over the past decade by developing animal protein free
microcarriers, protocols for a variety of cell culture based vaccines, and whole infected-cell harvest
The Company’s protocols are for producing human influenza vaccine via cell culture technology in
bioreactors using SoloHill’s Hillex ® microcarriers, Vero or MDCK cell lines and, animal protein free media.
SoloHill continues to seek partnerships and/or licensing arrangements with pharmaceutical manufacturers
that have an interest in utilizing microcarrier based cell culture technologies.
Source Signal Imaging, Inc.
San Diego, CA
Source Signal Imaging (SSI) provides innovative, powerful, and useable software to measure and visualize
human brain dynamics, used by researchers and clinicians worldwide. SSI specializes in advanced signal
and image processing, enabling investigators to combine electroencephalography (EEG),
magnetoencephalography (MEG) and magnetic resonance imaging (MRI) to determine where events
happen in the brain, how events change over time, and how brain regions interact. SSI’s EMSE®
software is used to study cognition, perception, and memory. Diseases such as autism, schizophrenia, and
epilepsy are characterized by disordered brain dynamics, and EMSE®
allows clinicians to better diagnose
and understand these diseases.
SpectraGenetics supplies the biomedical research market with innovative products for analyzing genes and
gene function. The company’s reporter-tagged full-length mammalian genes are sold to cell and molecular
biologists in academic, government and industrial laboratories. These products overcome many of the
drawbacks of currently available reporter systems, leading to more meaningful experimental data. The
company’s Peptide Mass Signature Genotyping (PMSG) products provide sensitive, comprehensive and
accurate sequence information particularly suited to clinical cancer research where existing sequencing
methods fail. RT-PMSG products for studies of gene expression, including alternative splicing, provide
complete characterization of variation using a single kit.
SpectRx, Inc. (OTCBB: SPRX) uses innovative and minimally invasive technologies in products and product
development activities for the diagnosis and therapy of cancer and diabetes. The company is currently in
FDA pivotal studies with its non-invasive cervical cancer detection product and is commercializing this
through its subsidiary, Guided Therapeutics, Inc. In the diabetes arena, the company has innovative
solutions for insulin delivery and glucose monitoring. SpectRx markets the SimpleChoice® line of diabetes
management products, which include insulin pump disposable supplies. SpectRx is also developing a
consumer device for continuous glucose monitoring.
San Diego, CA
Synthasome is a biotechnology company developing regenerative medicine products primarily for
musculoskeletal applications (tendon, ligament and cartilage repair), using tissue engineering technologies
supported by new intellectual property. The Company uses federal research grants to drive early product
development, and so far has received over $3 million in grants. The first product in our pipeline is a device
for assisting surgical repair of injured rotator cuff tendons (approx. $100 million market), the product is
anticipated to enter the market place in 2007, and will then be followed by products for knee articular
North Logan, UT
Tel: 435- 713-4917
SynVax, Inc. is a biopharmaceutical company with a mission to successfully discover, develop, and
commercialize pharmaceutical products for use in infection, pain, and cardiology. At least five significant
discoveries are currently ready for development, and more are in the pipeline. Animal studies have been
done on three products. The products are based on advanced peptide structure-function analyses and
expertise in peptide synthesis. Patent has been issued on one product and pending on another. The
pharmaceutical markets the company will address are currently in excess of $10 billion in annual sales.
SynZyme Technologies, LLC
SynZyme Technologies, LLC, is a privately-held, California-based, Delaware biopharmaceutical company.
Utilizing its proprietary platform technology of polynitroxylation, SynZyme is engaged in the development of
a drug pipeline based on targeted delivery of caged nitric oxide free radical therapeutics. These products
belong to a new class of stable, metal-free radicals with targeted antioxidant and enzyme-mimetic activities,
which are intended for the treatment of ischemia/reperfusion and inflammatory-related diseases associated
with inadequate blood flow.
Talaria Inc has a proprietary “builder” that enables development of healthcare eLearning programs over the
internet. This enables our content developers to originate, modify and publish sophisticated eLearning
programs from home or internet café anywhere in the world yet have the functionality of a desktop or server
This technology drastically reduces our cost of development by reducing travel costs and improving
workflow while also improving quality of content, by enabling content experts from anywhere in the world to
contribute without ever leaving home. Customers delighted by Talaria products include the US Army, VA,
major Pharmaceutical companies and hospitals.
The Quality Donor System (tm)(QDS), an FDA 510(k) cleared Medical Device, is Talisman's principal
achievement. It may be the world's only scientifically and medical production line proven automated
multimedia blood donor health history interviewing system. Since 2001 QDS has completed more than
450,000 interviews at five different blood and medical organizations and is currently operating at the rate of
350,000 interviews/year. It runs on tablet computers in standalone or network/Web modes. It has been
shown repeatedly to vastly increase donor and staff satisfaction, reduce FDA errors by over 60% and staff
time by over 80% and to increase donor honesty.
Talking Lights LLC
Talking Lights LLC uses existing lighting in a facility to create inexpensive unique communication networks
and precise locator capability. Lights become locator beacons while still providing non-flickering, strong
illumination. Applications include assistance for persons with cognitive disorders like Alzheimer's patients
and traumatic brain injury patients, wayfinding and guidance in retail facilities, office buildings, schools,
hospitals and care facilities, and specialized assistive areas like guidance for the blind. A capability like
GPS indoors is created.
Targeted Gene Delivery, Inc.
Targeted Gene Delivery, Inc., develops immune regulatory therapeutics derived from bacterial and viral
proteins. Bacteria and viruses have the ability to encode proteins designed to regulate the host immune
system. These proteins can be identified and modified to form unique therapeutics able to either enhance or
diminish the immune system. Therapeutics derived from these proteins have the potential to alter the
course of disease. Specific applications include anti-inflammatories for use in chronic diseases such as
septic shock and meningitis, and immune stimulatory products for use in immune compromised individuals.
Targeted Gene Delivery has developed a proprietary anti-inflammatory peptide with potential application in
the treatment of several chronic inflammatory diseases. The company is focused on the commercialization
of this novel therapeutic, and development of additional immune regulatory peptides.
TechEn designs, develops and markets non-invasive optical brain imaging solutions. The innovative,
portable devices are sold world-wide and provide fast quantitative assessment, reducing the cost for
treatment and improving rehabilitation. Working in conjunction with Harvard’s teaching hospital, MGH,
TechEn has developed propriety real-time algorithms, hardware, software and disposables. Current
applications include: stroke rehabilitation, traumatic brain injury, autism, epilepsy and early child
With twenty-two years experience in all stages of innovation, TechEn offers clients a full array of electronic
product design solutions and production services. Recent programs include Bone Densitometry, ICU
Glucose Monitor, GPS Signal Simulator and Wireless Biotech Sensing.
The Virtual Reality Medical Center
San Diego, CA
The Virtual Reality Medical Center (VRMC) delivers innovative pain distraction products using virtual reality
technology integrated with medical science. The patient wears a small, comfortable device with earphones
and a 3-D visual display that immerses them in an interactive world. Such immersion relieves pain by
reducing attention to it. VRMC-developed worlds include Enchanted Forest, Dream Castle, and others.
These pain distraction products are important adjuncts to other pain management methods, such as
pharmaceuticals, because the patient is more in control of managing his or her pain relief, thus reducing
medication and visits to health professionals.
Therapyx, Inc. is a privately held biopharmaceutical company that focuses on the development and
commercialization of nanoadjuvants for innovative therapeutic and vaccination strategies. The company’s
nanoadjuvant platform represents a general strategy for the immunotherapy of disease through the
application of slow-release
adjuvants. While the company’s first product is targeted for major cancers, including lung cancer (first
indication), breast cancer, melanoma and other solid tumors, Therapyx, Inc. has a broad pipeline of products
at the pre-clinical stage for applications in autoimmune
and infectious disease.
Therataxis models brain transport processes and designs delivery methods for therapies. The simulation
and prediction of transport mechanisms, and our proprietary direct delivery devices, provide the necessary
link in developing successful therapies of the brain by ensuring proper delivery. Our currently marketed
products are surgical simulation software and simulation-based device designs. We offer services in
medical image analysis, biomedical simulations, therapy planning, and management of appropriate
research. In addition to our industrial customers, the company has academic partnerships with major
universities through grants and contracts.
Our focus is to improve delivery of therapeutics directly into brain and other solid tissue (prostate, tumor,
etc.) by predicting the distribution of the therapy - either particulate or energy - for a specific individual and
Thromgen Inc., founded in 1995, is a privately owned early-stage biotechnology company that is discovering
and developing novel treatments for diseases related to a new class of thrombin receptor inhibitors (also
called antagonists or blockers). The novel mechanisms of the technology allows Thromgen’s therapeutic
scope to include cardiovascular-, oncologic-, and inflammatory-related diseases. Initially, the Company is
focusing on acute coronary syndromes and prostate cancer with its lead candidate, ThrombostatinTM. The
Company is a spin-out from the University of Michigan (Ann Arbor) located in Ann Arbor, Michigan.
Tissue Technologies LLC
Tissue Technologies LLC is a "start up" dedicated to healing and prevention of wounds. Our first product, a
protease sequestering dressing for chronic wounds is inexpensive and effective. We are developing other
materials for the same purpose which will be more potent and user friendly. Simiar products to treat gingivitis
and ostony wound sites are planned. Also under development is a bed-side color indicator for wound
protease activity which will help the caregiver decide on therapy. In addition, we have submitted a patent on
a device to prevent pressure ulcers. The protease sequestration technology will apply also to products to
prevent skin aging. Finally, TT wound prodcuts will be for animals as well as man.
TissueTech, Inc. & Bio-Tissue, Inc.
TissueTech uses its proprietary cyro-preservation technologies to produce amniotic membrane tissue
products with miraculous properties in promoting anti-inflammatory, anti-scarring and anti-angiogenic
actions. The Company’s two commercialized products (AmniGraft® and ProKera™) are targeted to restore
eye surface damages caused by corneal or conjunctival ulcers, chemical burns, and pterygium, etc. With
increasing number of publications since 1995, the concept of ocular surface reconstruction using these
products has gained popularity among ophthalmic community. This is proven by the exceptional growth the
Company experienced last year. The Company also has a pipeline includes several stem-cell therapies and
novel medical devices at different stages of development. The Company’s goal is to expand the therapeutic
actions of its tissue-engineered products to other body sites in the future.
TRS Technologies, Inc.
State College, PA
TRS is a producer of specialty piezoelectric products for navy sonar, medical ultrasound, precision sensor,
and precision positioning markets. TRS has been an innovator in the area of piezoelectric materials
technologies with developments such as new materials for high power sonar projectors; machinable
ceramics for the production of ultrasound arrays; high strength ceramics for high force actuators; and single
crystal piezoelectrics for broad band ultrasound transducers, high sensitivity vibration sensors, and high
displacement actuators. TRS currently has $4 million in annual sales and has received over $1 million in
investment capital for commercialization of new materials technologies.
VeriFax is a Chapter S Colorado Corporation. It is a small R&D enterprise with the main mission to develop
high quality, cost effective security and biomedical devices based on IP developed by the company
founders. The biomedical device “NeuroskillTM” is intended to assess fine motor control fluctuations in
people with neurological disorders, such as Parkinson’s disease and stroke, while “ImpairscopeTM” is a
device to assess impairment due to environmental intoxication and result of substance abuse. The
measures of impairment provided by Neuroskill and Impairscope can be considered as potential clinical
markers for prospective applications. The biometric device “AutographTM” offers an easy, cost-effective and
universally accepted solution for signature verification with unprecedented accuracy. It can be used in both
cyber security and physical security
Vesticon is focused on the development of a suite of interelated solutions to make it easier and more
lucrative for physicians to deal with one of the most frustrating areas in medicine: the diagnosis and
management of the dizzy patient. Building on the assets of medical expertise that is among the most
extensive for this field, Vesticon has funded operations through NIH SBIR grants, which now provide a
baseline to launch commercial activities to dominate the vestibular device market. Direct costs related to
injuries from elderly fallers with preventable vestibular problems exceed $10 billion; and Vesticon’s products
will penetrate a significant portion of this sector.
San Diego, CA
Vical's goal is to be an integrated biopharmaceutical company committed to the development and
commercialization of vaccines and immunotherapies based on its unique non-viral DNA technology.
Together with its licensees and collaborators, Vical is currently developing a number of vaccine and
therapeutic protein product candidates for the prevention or treatment of infectious diseases, cancer, and
cardiovascular diseases. Independent development programs include vaccines for CMV and anthrax, as
well as novel immunotherapeutics for treatment of melanoma. Through collaborations with others, Vical
leverages its technologies for applications that may not be appropriate for independent product development
efforts. Collaborators include Merck, Sanofi, Merial (Merck/Sanofi animal health joint venture), Aqua Health
(Novartis), AnGes MG, Corautus Genetics, and the NIH. In addition, Vical pursues contract manufacturing
opportunities to leverage its infrastructure and expertise in plasmid manufacturing, and to provide revenues
that contribute to its independent research and development efforts.
West Boylston, MA
Robert A. Peura
VivaScan Corporation has developed a painless testing device for blood glucose monitoring by means of
unique noninvasive infrared technology. Currently diabetic individuals stab themselves up to ten times per
day to determine their blood glucose, or inject insulin blindly at considerable risk of complications.
VivaScan’s monitor, designed by a team of technical and clinical experts, responds to the noninvasive test
needs of diabetic persons. A proprietary platform technology has evolved resulting in a personal hand held
monitor. With the patented VivaScan glucose tester, a simple and gentle squeeze of the ear or finger is all it
takes to get an accurate reading of blood glucose.
X-Ray Imaging Innovations
X-Ray Imaging Innovations is a company with expertise in medical x-ray imaging technology. The
company's current efforts are focused on the development of a novel bedside (portable) radiographic unit
and in improving general radiography and digital tomosynthesis. It is anticipated that the new portable x-ray
unit will be easy to use and will result in markedly improved images, images comparable in quality to those
currently obtained with fixed general radiographic units. It is also anticipated that the improvements we are
working on in general radiography and digital tomosynthesis will improve image quality in a dose efficient